This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pogacic, V. Articles by Schwaller, J. Search for Related Content PubMed PubMed Citation Articles by Pogacic, V. Articles by Schwaller, J.

Structural Analysis Identifies Imidazo[1,2-b]Pyridazines as PIM Kinase Inhibitors with In vitro Antileukemic Activity

¹ University Hospital Basel, Department of Research and the Hematology Clinic, Basel, Switzerland; ² Oxford University, Structural Genomics Consortium, Botnar Research Centre, Oxford, United Kingdom; and ³ Centro M. Tettamanti-Clinica Pediatrica Universita Milano-Bicocca, Monza, Italy

Requests for reprints: Juerg Schwaller, Department of Research, University Hospital Basel, Hebelstrasse 20, CH-4031 Basel, Switzerland. Phone: 41-61-265-3504; Fax: 41-61-265-2350; E-mail: J.Schwaller{at}unibas.ch or Stefan Knapp, Structural Genomics Consortium, Botnar Research Centre, Oxford University, Oxford OX3 7LD, United Kingdom. Phone: 44-1-865-227978; Fax: 44-1-865-737231; E-mail: stefan.knapp{at}sgc.ox.ac.uk.

Much attention has recently been focused on PIM kinases as potential targets for the treatment of hematopoietic malignancies and some solid cancers. Using protein stability shift assays, we identified a family of imidazo[1,2-b]pyridazines to specifically interact with and inhibit PIM kinases with low nanomolar potency. The high-resolution crystal structure of a PIM1 inhibitor complex revealed that imidazo[1,2-b]pyridazines surprisingly interact with the NH₂-terminal lobe helix C rather than with the kinase hinge region. Thus, the identified inhibitors are ATP competitive but not ATP mimetic compounds, explaining their enhanced selectivity with respect to conventional type I kinase inhibitors. One of the identified imidazo[1,2-b]pyridazines (K00135) was further tested in several hematopoietic cellular systems. First, K00135 dose-dependently impaired survival of murine Ba/F3 cells that have been rendered cytokine independent by overexpression of human PIMs. Second, K00135 impaired survival and clonogenic growth of a panel of human acute leukemia cells. Third, exposure of K00135 significantly suppressed in vitro growth of leukemic blasts from five acute myelogenous leukemia patients but not of normal umbilical cord blood mononuclear cells. In vitro kinase assays and immunoblotting using lysates from human MV4;11 leukemic cells showed inhibition of phosphorylation of known PIM downstream targets, such as BAD and eukaryotic translation initiation factor 4E–binding protein 1, by K00135. Taken together, we report a family of small molecules that selectively interact and block PIM kinases and could serve as a lead to develop new targeted antileukemic therapeutics. [Cancer Res 2007;67(14):6916–24]

This article has been cited by other articles:

				Z. Beharry, M. Zemskova, S. Mahajan, F. Zhang, J. Ma, Z. Xia, M. Lilly, C. D. Smith, and A. S. Kraft Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells Mol. Cancer Ther., June 1, 2009; 8(6): 1473 - 1483. [Abstract] [Full Text] [PDF]

				J. M. Gozgit, G. Bebernitz, P. Patil, M. Ye, J. Parmentier, J. Wu, N. Su, T. Wang, S. Ioannidis, A. Davies, et al. Effects of the JAK2 Inhibitor, AZ960, on Pim/BAD/BCL-xL Survival Signaling in the Human JAK2 V617F Cell Line SET-2 J. Biol. Chem., November 21, 2008; 283(47): 32334 - 32343. [Abstract] [Full Text] [PDF]

				M. Zemskova, E. Sahakian, S. Bashkirova, and M. Lilly The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer Cells J. Biol. Chem., July 25, 2008; 283(30): 20635 - 20644. [Abstract] [Full Text] [PDF]

				O. Fedorov, B. Marsden, V. Pogacic, P. Rellos, S. Muller, A. N. Bullock, J. Schwaller, M. Sundstrom, and S. Knapp A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases PNAS, December 18, 2007; 104(51): 20523 - 20528. [Abstract] [Full Text] [PDF]